VIDEO: Shorter duration Mavyret safe, effective in all HCV genotypes

BOSTON — In this exclusive video from The Liver Meeting 2019, Robert S. Brown Jr., MD, MPH, of Weill Cornell Medical College, discusses the results of the EXPEDITION-8 trial, which demonstrated that treatment with Mavyret over 8 weeks was effective and had a favorable safety profile in patients with treatment-naive chronic hepatitis C virus genotypes 1-6 and compensated cirrhosis.“We know we have a plethora of medications to choose [from] with hepatitis C, but the new recommendations from our organizations are to choose a pangenotypic therapy that is safe and effective,”Read More

Share on facebook
Share on twitter
Share on linkedin